A spin-off from Triton Systems (a longtime SBIR active firm), Sensera, Inc. is a development stage biological sensor company organized around products for the Point of Care (POC) clinical diagnostics market. The firm went Public on the Australian Stock Exchange in December 2016. Offering ER-A, a POC early and rapid analyzer for the early diagnosis of myocardial injury, ER-A includes a consumable sensor cartridge; and a reader device that measures the signal from the immunoassay, as well as transmits it visually, in print, or through wireless connectivity to the emergency clinical personnel. The driving force for the firm is development of cutting edge inexpensive sensors that detect the presence of chemicals, proteins and bio-organisms. Markets for the firm's sensors are in clinical diagnostics, drug discovery, and home test kits. The firm's sensors are based on conductive polymers and operate in real time with high sensitivity. The Company has a unique sensor array technology that allows rapid, highly sensitive detection of proteins and DNA sequences. The technology is protected by four patents and features femtomolar sensitivity, allowing it to detect proteins like cardiac markers at a concentration at least an order of magnitude lower than current state-of-the-art assays. Sensera is incorporating this technology into a Point of Care (POC) Early & Rapid Analyzer (ER-A) to address unmet needs in the field of emergency medicine. Sensera is positioning the (ER-A ) to initially address one rapidly growing market: Early Diagnosis of Myocardial Injury. ER-As high sensitivity for myocardial infarction indicators will enable the diagnosis of heart attacks (acute myocardial infarction or AMI) within two hours of the onset of chest pain, much earlier than possible with current tests. This eliminates the need for emergency personnel to wait for 6 hours in order to treat life-threatening AMI.
